Coatesville’s Courtyard by Marriott
The Waterford Hotel Group has announced the promotion of Claudine McGee-Bounds to General Manager of the 125-room Courtyard by Marriott in Coatesville. As General Manager, Bounds is responsible for all of the hotel’s operations, sales, and administration, as well as the associates employed at the property.
McGee-Bounds joined the Courtyard Coatesville team as Operations Manager before being promoted to General Manager. Prior to that, she was the General Manager for various brands, including Staybridge Suites, Summerfield Suites, and Candlewood Suites. She holds a bachelor’s degree in Hospitality Management from Johnson & Wales University.
The Waterford Hotel Group, a national hotel and convention center management firm, professionally manages the 125-room hotel.
Kennett Square-based Genesis HealthCare, a nursing home operator, said it will halt inpatient operations in eight mid-western states, divesting 61 facilities.
According to the Philadelphia Inquirer, the facilities in Kansas, Kentucky, Indiana, Iowa, Missouri, Montana, Nebraska, and Ohio have annual revenues of $432 million, or nine percent of inpatient revenue, but have been a disproportionate drag on earnings.
For the third quarter, Genesis had $1.42 billion in revenue, approximately equal to the same period a year ago. The company’s quarterly net loss was $20.46 million, an improvement over the $28.95 million it lost a year ago.
Wayne’s Egalet Corporation – a fully integrated specialty pharmaceutical company focused on developing, manufacturing, and commercializing innovative treatments for pain and other conditions – has reported financial results for the third quarter of 2016.
“Much progress was made in the third quarter with the successful FDA Advisory Committee meeting for ARYMO ER and the closing of a $40 million financing with a potential additional $40 million upon ARYMO ER approval,” said Bob Radie, president and CEO of Egalet. “We are now focused on working closely with the FDA to complete the regulatory review of ARYMO ER and preparing for a potential launch in the first quarter of 2017.”
ARYMO ER was developed for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.